Patents by Inventor Kenichiro Takagi
Kenichiro Takagi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240120264Abstract: The first conductive part includes a first surface layer part and a first inner layer part constituting a layer different from the first surface layer part in the substrate. The second conductive part includes a second surface layer part facing the first surface layer part with a creeping distance therebetween, and a second inner layer part constituting a layer different from the second surface layer part in the substrate. The electronic apparatus is provided with at least one of a first protruded configuration and a second protruded configuration. The first protruded configuration is configured such that the first inner layer part includes a first conductive protrusion protruding towards the second conductive part from the first surface layer part. The second protruded configuration is configured such that the second inner layer part includes a second conductive protrusion protruding towards the first conductive part from the second surface layer part.Type: ApplicationFiled: December 5, 2023Publication date: April 11, 2024Applicant: DENSO CORPORATIONInventors: Kenichiro TAKAGI, Akira TOKUMASU
-
Publication number: 20240112967Abstract: An electronic device includes a substrate and circuitry mounted thereon. In plan view in a thickness direction of the substrate, the first conductive portion includes a rounded convex corner, and the second conductive portion includes a concave corner facing the convex corner. Extensions of two straight lines contiguous to the convex corner intersect at a first apex of a convex angle. Extensions of two straight lines contiguous to the concave corner intersect at a second apex of a concave angle. A distance between a convex corner point and a concave corner point is greater than a distance between the first apex and the second apex, where the convex corner point is an intersection of a corner line passing through the first apex and the second apex, and the convex corner, and the concave corner point is an intersection of the corner line and the concave corner.Type: ApplicationFiled: December 8, 2023Publication date: April 4, 2024Applicant: DENSO CORPORATIONInventors: Kenichiro TAKAGI, Akira TOKUMASU
-
Publication number: 20230192868Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.Type: ApplicationFiled: March 2, 2023Publication date: June 22, 2023Applicant: Teijin Pharma LimitedInventors: Hiroshi EGUCHI, Akira Tanokura, Kenichiro Takagi, Hirotsugu KATO, Satoshi YAMAMURA, Naoko NAMIKI
-
Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies
Patent number: 11629194Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.Type: GrantFiled: May 29, 2018Date of Patent: April 18, 2023Assignee: Teijin Pharma LimitedInventors: Hiroshi Eguchi, Akira Tanokura, Kenichiro Takagi, Hirotsugu Kato, Satoshi Yamamura, Naoko Namiki -
Publication number: 20220033485Abstract: Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.Type: ApplicationFiled: December 2, 2019Publication date: February 3, 2022Applicant: Teijin Pharma LimitedInventors: Akira TANOKURA, Hirotsugu KATO, Hiroshi EGUCHI, Kenichiro TAKAGI, Satoshi YAMAMURA, Naoko NAMIKI, Daisuke ISHIKAWA, Hirofumi HIGUCHI, Tomoyo TAKEO, Masayo OHORI
-
Patent number: 10689354Abstract: A compound, represented by the following formula or a medically acceptable salt thereof, having an effect of regulating the activity of an androgen receptor. In the formula, X represents S, O; Z represents (Ra)n-A-(CR13R14)0-1—(CR11R12)0-1; A represents aryl, heteroaryl; R1 represents alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl; R2 represents hydrogen, halogen, alkyl, cycloalkyl, phenyl; R3 represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl, acyl, cycloalkylcarbonyl, benzoyl, spiroalkyl, adamantyl, silyl, R31R32NCO—; R4 and R5 represent hydrogen, halogen, alkyl, phenyl, and cycloalkyl.Type: GrantFiled: December 9, 2016Date of Patent: June 23, 2020Assignee: Teijin Pharma LimitedInventors: Shinnosuke Hosoda, Gen Unoki, Hidekazu Watanabe, Kosuke Sasaki, Jun Shibata, Emi Yokoyama, Kyohei Horie, Kenichiro Takagi
-
Publication number: 20200115460Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.Type: ApplicationFiled: May 29, 2018Publication date: April 16, 2020Applicant: TEIJIN PHARMA LIMITEDInventors: Hiroshi EGUCHI, Akira TANOKURA, Kenichiro TAKAGI, Hirotsugu KATO, Satoshi YAMAMURA, Naoko NAMIKI
-
Publication number: 20190031628Abstract: A compound, represented by the following formula or a medically acceptable salt thereof, having an effect of regulating the activity of an androgen receptor. In the formula, X represents S, O; Z represents (Ra)n-A- (CR13R14)0-1—(CR11R12)0-1; A represents aryl, heteroaryl; R1 represents alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl; R2 represents hydrogen, halogen, alkyl, cycloalkyl, phenyl; R3 represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl, acyl, cycloalkylcarbonyl, benzoyl, spiroalkyl, adamantyl, silyl, R31R32NCO—; R4 and R5 represent hydrogen, halogen, alkyl, phenyl, and cycloalkyl.Type: ApplicationFiled: December 9, 2016Publication date: January 31, 2019Applicant: Teijin Pharma LimitedInventors: Shinnosuke HOSODA, Gen UNOKI, Hidekazu WATANABE, Kosuke SASAKI, Jun SHIBATA, Emi YOKOYAMA, Kyohei HORIE, Kenichiro TAKAGI
-
Patent number: 9006220Abstract: To provide a novel vitamin D3 derivative useful as a therapeutic agent for osteoporosis. Provided is a vitamin D3 derivative represented by the following formula (1) or a medicinally acceptable solvate thereof: wherein R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkylcarbonyloxyalkyl group with each alkyl having 1 to 6 carbon atoms, or an arylcarbonyloxyalkyl group with the aryl having 6 to 10 carbon atoms and the alkyl having 1 to 6 carbon atoms; R2 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or, together with the other R2 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; R3 represents an alkyl group having 1 to 6 carbon atoms or, together with the other R3 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; X represents an oxygen atom or a methylene group; and n represents an integer of 1 or 2.Type: GrantFiled: October 24, 2011Date of Patent: April 14, 2015Assignee: Teijin Pharma LimitedInventors: Hiroshi Saito, Masato Komiyama, Eiji Ochiai, Kenichiro Takagi, Takayuki Chida, Mariko Fujita, Keiichiro Imaizumi, Toshiyuki Kaneko
-
Publication number: 20130210781Abstract: To provide a novel vitamin D3 derivative useful as a therapeutic agent for osteoporosis. Provided is a vitamin D3 derivative represented by the following formula (1) or a medicinally acceptable solvate thereof: wherein R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkylcarbonyloxyalkyl group with each alkyl having 1 to 6 carbon atoms, or an arylcarbonyloxyalkyl group with the aryl having 6 to 10 carbon atoms and the alkyl having 1 to 6 carbon atoms; R2 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or, together with the other R2 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; R3 represents an alkyl group having 1 to 6 carbon atoms or, together with the other R3 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; X represents an oxygen atom or a methylene group; and n represents an integer of 1 or 2.Type: ApplicationFiled: October 24, 2011Publication date: August 15, 2013Applicant: TEIJIN PHARMA LIMITEDInventors: Hiroshi Saito, Masato Komiyama, Eiji Ochiai, Kenichiro Takagi, Takayuki Chida, Mariko Fujita, Keiichiro Imaizumi, Toshiyuki Kaneko
-
Publication number: 20100216747Abstract: An object of the present invention is to provide a preventive drug and a therapeutic drug for diseases caused by abnormal bone metabolism, especially osteoporosis, which is more effective than conventional drugs. Combined use of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or a salt thereof; and at least one compound selected from the group consisting of etidronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and salts thereof can exert higher bone resorption inhibitory effect and provide a preventive effect and a therapeutic effect for diseases caused by abnormal bone metabolism, especially osteoporosis as compared with administration of the respective agents respectively.Type: ApplicationFiled: August 1, 2008Publication date: August 26, 2010Applicant: TEIJIN PHARMA LIMITEDInventors: Eiji Ochiai, Miyuki Nishiga, Kenichiro Takagi, Yoshiaki Azuma
-
Publication number: 20080287544Abstract: The present invention provides a method for screening a substance having a thermogenesis enhancing effect containing a compound having an effect activating PPAR?, an agent containing the compound, and an agent having antidiabetic, antiobestic or visceral accumulated fat-lowering function. The present invention provides an agent containing a compound having an effect activating PPAR?, which is a peroxisome proliferator activated receptor, and having effects which enhances nonshivering thermogenesis (nST), specifically enhances uncoupling respiration in mitochondria of cells in an adipose tissue or the like, or proton leak in inner membranes of mitochondria, and increases the amount of expression of UCP1, and provides an antidiabetic agent, an antiobestic gent and a visceral accumulated fat-lowering agent containing the compound. Further, the present invention provides a method for screening the compound by measuring a PPAR? activating effect.Type: ApplicationFiled: June 19, 2008Publication date: November 20, 2008Applicant: Teijin LimitedInventors: Kazuyoshi YAMAOKA, Kenichiro Takagi, Kenichiro Kataoka, Masanori Yamamoto, Toshihiro Chikanishi
-
Patent number: 7396642Abstract: The present invention provides a method for screening a substance having a thermogenesis enhancing effect containing a compound having an effect activating PPAR ?, an agent containing the compound, and an agent having antidiabetic, antiobestic or visceral accumulated fat-lowering function. The present invention provides an agent containing a compound having an effect activating PPAR ?, which is a peroxisome proliferator activated receptor, and having effects which enhances nonshivering thermogenesis (nST), specifically enhances uncoupling respiration in mitochondria of cells in an adipose tissue or the like, or proton leak in inner membranes of mitochondria, and increases the amount of expression of UCP1, and provides an antidiabetic agent, an antiobestic gent and a visceral accumulated fat-lowering agent containing the compound. Further, the present invention provides a method for screening the compound by measuring a PPAR ? activating effect.Type: GrantFiled: July 17, 2002Date of Patent: July 8, 2008Assignee: Teijin LimitedInventors: Kazuyoshi Yamaoka, Kenichiro Takagi, Kenichiro Kataoka, Masanori Yamamoto, Toshihiro Chikanishi
-
Publication number: 20040265817Abstract: The present invention provides a method for screening a substance having a thermogenesis enhancing effect containing a compound having an effect activating PPAR &dgr;, an agent containing the compound, and an agent having antidiabetic, antiobestic or visceral accumulated fat-lowering function.Type: ApplicationFiled: January 14, 2004Publication date: December 30, 2004Inventors: Kazuyoshi Yamaoka, Kenichiro Takagi, Kenichiro Kataoka, Masanori Yamamoto, Toshihiro Chikanishi
-
Patent number: 5804410Abstract: This invention provides a nucleic acid sequence encoding a trypsin-like enzyme which can be present at the trachea of human lungs, and can selectively digest a synthetic substrate for trypsin and a synthetic substrate for thrombin, and fibrinogen; and a process for producing the trypsin-like enzyme by genetic engineering utilizing the nucleic acid sequence.Type: GrantFiled: July 28, 1995Date of Patent: September 8, 1998Assignee: Teijin LimitedInventors: Kazuyoshi Yamaoka, Hiroko Ogawa, Yoshinori Sugimoto, Kenichi Masuda, Tetsuya Suga, Kenichiro Takagi, Susumu Yasuoka